200 related articles for article (PubMed ID: 30027852)
1. A Case of Severe Transaminase Elevation Following a Single Ustekinumab Dose with Remission After Drug Withdrawal.
Lovero R; Losurdo G; Mastromauro M; Castellaneta NM; Mongelli A; Gentile A; Di Leo A; Principi M
Curr Drug Saf; 2018; 13(3):221-223. PubMed ID: 30027852
[TBL] [Abstract][Full Text] [Related]
2. Liver Injury in Psoriasis Patients Receiving Ustekinumab: A Retrospective Study of 44 Patients Treated in the Clinical Practice Setting.
Llamas-Velasco M; Concha-Garzón MJ; García-Diez A; Daudén E
Actas Dermosifiliogr; 2015; 106(6):470-6. PubMed ID: 25912374
[TBL] [Abstract][Full Text] [Related]
3. The safety of ustekinumab for the treatment of psoriatic arthritis.
López-Ferrer A; Laiz A; Puig L
Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on ustekinumab in moderate to severe plaque psoriasis.
Croxtall JD
Am J Clin Dermatol; 2012 Apr; 13(2):135-7. PubMed ID: 22201419
[TBL] [Abstract][Full Text] [Related]
5. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
Kurzeja M; Rudnicka L; Olszewska M
Am J Clin Dermatol; 2011 Apr; 12(2):113-25. PubMed ID: 21348542
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
van Vollenhoven RF; Hahn BH; Tsokos GC; Wagner CL; Lipsky P; Touma Z; Werth VP; Gordon RM; Zhou B; Hsu B; Chevrier M; Triebel M; Jordan JL; Rose S
Lancet; 2018 Oct; 392(10155):1330-1339. PubMed ID: 30249507
[TBL] [Abstract][Full Text] [Related]
7. Ustekinumab associated with flares of psoriatic arthritis.
Stamell EF; Kutner A; Viola K; Cohen SR
JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
[TBL] [Abstract][Full Text] [Related]
8. Use of ustekinumab in five psoriatic patients with hepatitis B virus infection.
Piaserico S; Conti A; Coati I; Galdo G; Bernabucci V; Zanca A; Drabeni M; Masutti F; Musumeci ML; Alberti A; Russo FP
G Ital Dermatol Venereol; 2019 Jun; 154(3):376-377. PubMed ID: 28712266
[No Abstract] [Full Text] [Related]
9. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.
Tsai TF; Ho V; Song M; Szapary P; Kato T; Wasfi Y; Li S; Shen YK; Leonardi C;
Br J Dermatol; 2012 Nov; 167(5):1145-52. PubMed ID: 22803615
[TBL] [Abstract][Full Text] [Related]
10. Two cases of hepatitis B in patients with moderate to severe psoriasis with ustekinumab.
Opel D; Economidi A; Chan D; Wasfi Y; Mistry S; Vergou T; Antoniou C; Sofen H
J Drugs Dermatol; 2012 Dec; 11(12):1498-501. PubMed ID: 23377523
[TBL] [Abstract][Full Text] [Related]
11. Ustekinumab does not increase tuberculosis risk: Results from a national database in South Korea.
Cho SI; Kang S; Kim YE; Lee JY; Jo SJ
J Am Acad Dermatol; 2020 May; 82(5):1243-1245. PubMed ID: 31866266
[No Abstract] [Full Text] [Related]
12. Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in a Psoriasis Patient Treated With Ustekinumab.
Dickson L; Menter A
J Drugs Dermatol; 2017 Feb; 16(2):177-179. PubMed ID: 28300862
[TBL] [Abstract][Full Text] [Related]
13. Varicella zoster virus meningitis under ustekinumab because of plaque psoriasis.
Stöllberger C; Finsterer J
J Dermatol; 2017 Jun; 44(6):703-705. PubMed ID: 28150333
[TBL] [Abstract][Full Text] [Related]
14. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
[TBL] [Abstract][Full Text] [Related]
15. [Ustekinumab-induced eosinophilic pneumonia during the course of ustekinumab therapy for plaque psoriasis].
Amy de la Bretèque M; Appere-De Vecchi C; Zeboulon C; Zaien I; Sigal ML; Mahé E
Ann Dermatol Venereol; 2015 Mar; 142(3):193-6. PubMed ID: 25624139
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Leonardi CL; Kimball AB; Papp KA; Yeilding N; Guzzo C; Wang Y; Li S; Dooley LT; Gordon KB;
Lancet; 2008 May; 371(9625):1665-74. PubMed ID: 18486739
[TBL] [Abstract][Full Text] [Related]
17. The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis.
Zabotti A; Goletti D; Lubrano E; Cantini F
Expert Opin Drug Saf; 2020 Jan; 19(1):69-82. PubMed ID: 31847608
[No Abstract] [Full Text] [Related]
18. Thrombocytopenia in a psoriatic patient sequentially treated with adalimumab, secukinumab and ustekinumab.
Nakahara T; Konishi S; Yasukochi Y; Esaki H; Tsuji G; Kido-Nakahara M; Furue M
J Dermatol; 2019 May; 46(5):e157-e158. PubMed ID: 30353917
[No Abstract] [Full Text] [Related]
19. Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients.
Jones BB; Millsop JW; Walsh JA; Krueger GG; Callis Duffin K
Br J Dermatol; 2015 Jul; 173(1):272-4. PubMed ID: 25557081
[No Abstract] [Full Text] [Related]
20. Risankizumab for the treatment of psoriasis.
Gu C; Yang J
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):851-857. PubMed ID: 31460804
[No Abstract] [Full Text] [Related]
[Next] [New Search]
